Abstract
We have read with interest the early release paper by Neelakantan et al. regarding platelet dysfunction associated with ponatinib in patients with chronic myeloid leukemia (CML) resistant to multiple tyrosine kinase inhibitors (TKI) therapy.[1][1] The authors have shown a prolonged closure time with
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
